Why Motilal Oswal is still bullish on SBI Life (NSE: SBILIFE) despite trimming its price target ahead of IRDAI commission reform

SBI Life Insurance Company Limited (NSE: SBILIFE), one of India’s largest private life insurers, has received a reaffirmed Buy rating from Motilal Oswal Financial Services, which has simultaneously trimmed its 12-month price target to Rs 2,400 from Rs 2,570 per share. The revised target implies an upside of approximately 24 per cent from the stock’s previous close near Rs 1,935, placing the insurer firmly in bullish territory for institutional investors. Motilal Oswal anchors its constructive view on SBI Life Insurance’s structural growth advantages, including its deep penetration of the State Bank of India branch network, a large and expanding agency force, and a deliberate pivot toward higher-margin product lines. The target revision, rather than a downgrade in conviction, reflects a recalibration of near-term assumptions following fresh regulatory signals from the Insurance Regulatory and Development Authority of India on distribution commission structures.

Why has Motilal Oswal revised its SBI Life Insurance target price lower despite maintaining a Buy call?

The target reduction from Rs 2,570 to Rs 2,400 is a function of risk-adjusted modelling rather than deteriorating fundamentals. The Insurance Regulatory and Development Authority of India is actively deliberating changes to the commission structure governing life insurance distribution, with proposals on the table including staggered commission payments and product-specific caps on distribution fees. For a company where bancassurance through State Bank of India’s retail branches contributes a significant share of new business premiums, even modest regulatory intervention in commission economics can have an outsized effect on partner incentive structures and therefore on near-term new business growth rates.

Motilal Oswal’s report does not argue that the regulatory risk will be fatal to SBI Life Insurance’s model. It argues that it introduces timing uncertainty around the pace of distribution expansion and that commission renegotiations with bancassurance partners, including associated banks, are likely if the regulatory caps materialise in a sharp form. The brokerage’s offsetting view is that SBI Life Insurance is structurally better positioned to absorb this disruption than most peers, because its commission ratio of approximately 4.8 per cent in the first nine months of FY26 sits meaningfully below the industry average. Lower absolute commission dependency means less to renegotiate and a narrower delta between pre- and post-regulatory economics.

How does SBI Life Insurance’s annualised premium equivalent growth compare with the broader Indian life insurance industry?

SBI Life Insurance has compounded new business annualised premium equivalent at 15 per cent annually over the period FY20 through FY25, against an industry average of 6 per cent over the same window. That sustained outperformance is not simply a function of riding the State Bank of India distribution network; it reflects a disciplined expansion of the agency channel and improving productivity per agent. In the year to date for FY26, annualised premium equivalent growth has continued at 15 per cent year on year, ahead of the 13 per cent growth recorded for the industry in the same period.

Motilal Oswal’s base case is that this 15 per cent growth trajectory holds broadly stable through FY26, FY27, and FY28, aided by three structural enablers: deeper penetration of the SBI bancassurance ecosystem, continued improvement in agent productivity through better training and digital tools, and a favourable product mix shift. The brokerage characterises SBI Life Insurance as a consistent compounder in the private life insurance segment, a label that carries some weight given that India’s life insurance penetration remains well below global averages and the addressable market is expanding as household incomes rise and awareness of protection products increases.

What is driving SBI Life Insurance’s product mix shift away from ULIPs toward traditional and protection products?

Unit-linked insurance plans currently account for approximately 67 per cent of SBI Life Insurance’s individual annualised premium equivalent. That figure is high relative to peers and has historically compressed the company’s value of new business margin, because ULIPs generate lower margin than traditional savings or protection products. SBI Life Insurance’s management and its investors have flagged this mix imbalance as a medium-term drag on profitability, and the company has been actively steering the portfolio toward a more balanced composition.

Motilal Oswal’s report expects the ULIP share to decline gradually toward 60 per cent of individual annualised premium equivalent over time, as non-participating savings, participating traditional products, and protection policies take a larger share of new business. The protection segment is growing significantly faster than the overall portfolio, and management has set a medium-term target to raise protection’s contribution to 9 to 9.5 per cent of individual annualised premium equivalent, compared with its current level. Rider attachment rates are also rising, adding premium income with minimal incremental acquisition cost. This product evolution is the primary mechanism through which Motilal Oswal expects value of new business margins to expand from their current level.

What is Motilal Oswal’s forecast for SBI Life Insurance’s value of new business margin trajectory through FY28?

SBI Life Insurance’s value of new business margin for the nine months of FY26 stood at 27.2 per cent, representing a 30 basis point improvement year on year. The margin figure carries a 110 basis point headwind from the loss of input tax credit following the goods and services tax exemption change for life insurance premiums. Adjusting for this item, the underlying margin trajectory is stronger than the headline number suggests.

Motilal Oswal’s projections place the value of new business margin in a range of 26 to 28 per cent through the near term, supported by a richer product mix, operational efficiency gains, and increasing rider income. The brokerage projects a further 50 basis point expansion in FY27, and another 50 basis point improvement in FY28, taking the margin to approximately 28.5 per cent by the end of the forecast window. Combined with the sustained annualised premium equivalent growth outlook, this supports an estimate of 18 per cent or higher operating return on embedded value going forward. The valuation underpinning the Rs 2,400 target is based on 2.2 times the estimated price-to-embedded-value multiple for FY28.

How could IRDAI’s proposed commission reforms affect SBI Life Insurance’s bancassurance distribution model and near-term growth?

The Insurance Regulatory and Development Authority of India’s potential commission reforms represent the single most consequential near-term risk in Motilal Oswal’s thesis on SBI Life Insurance. Bancassurance, the sale of insurance products through a bank’s branch network, has been the cornerstone of SBI Life Insurance’s new business engine since inception. The model works because branch staff earn commissions on policies sold, creating aligned incentives between the insurer and its distribution partner. If commission caps reduce the earning potential for bancassurance staff, the structural economics of this model change, and not in the insurer’s favour.

The mitigant Motilal Oswal points to is SBI Life Insurance’s relatively lean commission structure. A commission ratio of 4.8 per cent in 9MFY26, well below the industry average, suggests the company has already been operating with discipline on distribution costs. If the regulatory floor is set near where SBI Life Insurance already operates, the disruption to its economics may be limited to transition friction. The risk scenario, however, is one where sharp caps force a renegotiation of existing bancassurance arrangements, introduce product refiling requirements, and trigger a temporary pause in new business origination while distribution partners adjust. The brokerage characterises this as a near-term risk rather than a structural challenge, and the Buy rating implies confidence that the company navigates it without permanent damage to its growth profile.

Where is SBILIFE trading relative to its 52-week range and what does the current market price imply for investors?

SBI Life Insurance shares have traded in a 52-week range of Rs 1,382.65 to Rs 2,132.00 on the NSE, with the stock recently in the Rs 1,915 to Rs 1,940 band. The stock reached its all-time high of Rs 2,132 in late February 2026, before pulling back in March amid broader market softness. The market capitalisation stands at approximately Rs 1.94 trillion, reflecting SBI Life Insurance’s position as one of the largest private life insurers by market value in India.

Against Motilal Oswal’s revised target of Rs 2,400, the current trading range implies upside of roughly 23 to 25 per cent, consistent with the brokerage’s stated 24 per cent upside figure. The consensus among 34 analysts tracked by market data aggregators is a Buy, with an average 12-month price target of approximately Rs 2,389, broadly aligned with Motilal Oswal’s revised estimate. The stock’s current price-to-earnings multiple of approximately 78 to 80 times trailing earnings reflects a premium valuation that is typical for high-quality private sector life insurers in India, where the market prices in long compounding runways rather than near-term earnings. The key question for the stock in the coming months is whether the IRDAI commission reform timeline crystallises, and if it does, whether the market treats it as a temporary disruption or a structural repricing event.

Key takeaways: What Motilal Oswal’s revised SBI Life Insurance call means for investors and the private life insurance sector

• Motilal Oswal Financial Services has maintained a Buy rating on SBI Life Insurance Company Limited (NSE: SBILIFE) while trimming its 12-month target to Rs 2,400 from Rs 2,570, implying approximately 24 per cent upside from recent trading levels near Rs 1,935.
• The target revision reflects regulatory risk from the Insurance Regulatory and Development Authority of India’s proposed commission reform, not deteriorating business fundamentals. The brokerage’s long-term conviction on the stock remains intact.
• SBI Life Insurance has delivered annualised premium equivalent growth of 15 per cent per year over FY20 to FY25, more than double the industry’s 6 per cent pace over the same period, establishing its credentials as a structural compounder in private life insurance.
• The company’s commission ratio of approximately 4.8 per cent in 9MFY26 is materially below the industry average, providing a relative buffer against potential bancassurance economics disruption if commission caps are implemented.
• A deliberate portfolio rebalancing from unit-linked insurance plans toward traditional savings, participating, and protection products is the primary driver of projected value of new business margin expansion, with Motilal Oswal forecasting margins reaching 28.5 per cent by FY28.
• The protection segment is growing significantly faster than the overall portfolio, with management targeting its contribution to individual annualised premium equivalent to reach 9 to 9.5 per cent, up from current levels, supporting long-term margin improvement.
• Motilal Oswal expects operating return on embedded value of 18 per cent or above going forward, supported by sustainable double-digit annualised premium equivalent growth and steady margin progression.
• The consensus target among 34 analysts covering the stock is approximately Rs 2,389, with a unanimous Buy orientation, indicating broad institutional alignment with the bullish view on SBI Life Insurance.
• Near-term catalysts include regulatory clarity on the IRDAI commission framework and SBI Life Insurance’s Q4 FY26 results, scheduled for April 23, 2026, which will provide updated guidance on distribution trends and product mix progression.
• The IRDAI commission reform risk, if it materialises sharply, carries industry-wide implications for private life insurers relying on bancassurance distribution, making SBI Life Insurance’s February-March correction an observable stress test for the broader sector.